文献速递免疫规划传染病防控与疫情报告

尼泊尔儿童单剂伤寒结合疫苗5年免疫应答持久性

Persistence of immune responses 5 years after vaccination with a single dose of typhoid conjugate vaccine (TCV) in Nepalese children.
PubMed 文献 · Vaccine · 2026-09-05

在尼泊尔开展参与者与观察者盲法随机试验,2万余名9月龄至16岁儿童随机接种单剂Typbar TCV或MenA结合疫苗,免疫原性亚组随访5年。结果显示抗Vi IgG几何平均浓度从第28天2037.90降至第5年109.3,但88%参与者维持≥4倍升高,表明免疫至少持续5年。

要点

  • 单剂TCV接种后5年,88%儿童抗Vi IgG较基线仍保持≥4倍升高。
  • 抗Vi IgG几何平均浓度从第28天2037.90降至第5年109.3。
  • 年龄较小儿童抗体衰减更快,提示需研究最佳接种年龄与加强针。

核心结论

  • 单剂伤寒结合疫苗诱导的抗Vi免疫至少持续5年。
  • 年幼接种者抗体衰减更快,需进一步研究最佳接种年龄和加强针需求。

研究设计与样本

  • 在尼泊尔Lalitpur开展的参与者与观察者盲法随机对照试验(2017-2021,ISRCTN43385161)。
  • 20,019名9月龄至≤16岁儿童随机接种Typbar TCV或MenA结合疫苗,2020-2021揭盲后交叉接种并随访至2025年。
  • 免疫原性亚组1500人(Vi-TT 1000人,MenA 500人)在基线、第28天、第18个月、第2、4、5年采血。

主要发现

  • 抗Vi IgG几何平均浓度第28天为2037.90(95%CI 1904.86-2180.23),第18个月降至241.29(220.27-264.31),第5年为109.3(98.65-121.10)。
  • 第5年时88%参与者抗Vi IgG较基线维持≥4倍升高。
  • 年龄较大儿童、女性及基线可检出抗Vi IgG者的抗体衰减显著更慢。
  • 抗Vi IgA与IgG高度相关(p<0.0001)。

临床怎么用

  • 单剂TCV在伤寒流行区可提供至少5年的免疫保护,支持现有单剂接种推荐。
  • 对年幼接种儿童应关注抗体衰减,未来可能需要加强免疫。

局限性

  • 免疫原性分析仅基于1500人亚组,非全部试验人群。
  • 原文未报告5年随访期间临床伤寒发病的保护效果数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A single-dose typhoid conjugate vaccine (TCV) has been recommended in endemic settings. Here we report the 5-year immunogenicity results post a single dose of TCV in Nepal. METHODS: We conducted a participant- and observer-blinded randomised trial (RCT) in Lalitpur, Nepal (2017-2021) (ISRCTN43385161). 20,019 children aged 9 months to ≤16 years were randomised to receive Typbar TCV (Vi-TT; Bharat Biotech International, India) or capsular group A meningococcal conjugate vaccine (MenA) in 2017-2018. After unblinding in 2020-2021, children were offered the alternate vaccine and were followed until 2025. A subgroup of 1500 participants (1000 Vi-TT, 500 MenA) were recruited into the immunogenicity cohort, who had blood samples taken at Day 0, Day 28, Month 18, Years 2, 4, and 5 post-baseline. The primary outcome is anti-Vi antibody responses. RESULTS: The median age at TCV vaccination was 10.1 in the 2017/2018 cohort and 13.1 in the 2020/2021 cohort. The geometric mean concentration (GMC) of anti-Vi IgG was 2037.90 (95% CI: 1904.86-2180.23) at Day 28, dropping to 241.29 (220.27-264.31) at Month 18. At Year 5 post-vaccination, the GMC was 109.3 (98.65-121.10). The proportion of participants maintaining a ≥4-fold rise at Year 5 post-vaccination from baseline remained high (88%). Antibody decay was significantly slower in older children, females, and children with detectable baseline anti-Vi IgG, compared with their respective reference groups. Anti-Vi IgA was highly correlated with IgG (p < 0.0001). CONCLUSIONS: This study provides evidence that anti-Vi immunity is sustained for at least 5 years post-vaccination. Children vaccinated at younger ages showed a faster decline, highlighting the need for further investigation into the optimal age for vaccination and the need for boosters. FUNDING: Wellcome Trust.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Pant D, Zhang Y, Feaheny F, et al. Persistence of immune responses 5 years after vaccination with a single dose of typhoid conjugate vaccine (TCV) in Nepalese children. Vaccine. 2026. PMID: 42700746. doi:10.1016/j.vaccine.2026.129130

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。